Bone health and osteoporosis: The role of vitamin K and potential antagonism by anticoagulants

Nutrition in Clinical Practice

Volumn 22, Issue 5, 2007, Pages 517-544

  Pearson, Debra A ^a  

^a UNIVERSITY OF WISCONSIN GREEN BAY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ALFACALCIDOL; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CALCITONIN; CALCIUM; COLECALCIFEROL; COUMARIN; COUMARIN ANTICOAGULANT; DICOUMAROL; ERGOCALCIFEROL; HYDROXYPROLINE; LEUPRORELIN; MENADIONE; MENAQUINONE; MENATETRENONE; OSTEOCALCIN; OSTEOPROTEGERIN; PHENPROCOUMON; PHYTOMENADIONE; PLACEBO; PREDNISOLONE; VITAMIN D; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; COUMARIN DERIVATIVE;

ANTICOAGULANT THERAPY; BONE DENSITY; BONE METABOLISM; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG POTENTIATION; EMBRYOPATHY; FRACTURE; HUMAN; LONG TERM CARE; NONHUMAN; NUTRITIONAL ASSESSMENT; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VITAMIN K METABOLISM; VITAMIN SUPPLEMENTATION; BONE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NUTRITIONAL REQUIREMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; TIME; VITAMIN K DEFICIENCY;

ANTICOAGULANTS; BONE AND BONES; BONE DENSITY; COUMARINS; HUMANS; NUTRITIONAL REQUIREMENTS; OSTEOCALCIN; OSTEOPOROSIS; RISK FACTORS; TIME FACTORS; VITAMIN K; VITAMIN K DEFICIENCY;

EID: 38749098188     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426507022005517     Document Type: Review

References (205)

1. Cockayne S, Adamson J, Lanhamp-New S, Shearer MJ, Gilbody S, Torgerson DJ. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1256-1261.
2. Vermeer C, Shearer MJ, Zitterman A, et al. Beyond deficiency: potential benefits of increased intakes of vitamin K for bone and vascular health. Eur J Clin Nutr. 2004;43:325-335.
3. Weber P. Vitamin K and bone health. Nutrition. 2001;17:880-887.
4. Hauschka PV, Lian JB, Cole DE, Gundberg C. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989;69:990-1047.
5. Menon RK, Gill DS, Thoms M, Kernoff PB, Dandona P. Impaired carboxylation of osteocalcin in warfarin-treated patients. J Clin Endocrinol Metab. 1987;64:59-61.
6. Price PA, Otsuka AS, Poser JW, Kristaponis J, Raman N. Characterization of a γ-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci U S A. 1976;73:1447-1451.
7. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin. Arch Intern Med. 2006;166:241-246.
8. Caraballo PJ, Heit JA, Atkinson EJ, et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med. 1999;159:1750-1756.
9. Guillaumont M, Weiser H, Sann L, Vignal B, Ledercq M, Drederich A. Hepatic concentration of vitamin K active compounds after application of phylloquinone to chickens on a vitamin K deficient or adequate diet. Int J Vitam Nutr Res. 1992;62:15-20.
10. Sakamoto N, Kimura M, Hiraike H, Itokawa Y. Changes of phylloquinone and menaquinone-4 concentrations in rat liver after oral, intravenous and intraperitoneal administration. Int J Vitam Nutr Res. 1996;66:322-328.
11. Thijssen HH, Drittij-Reijnders MJ. Vitamin K distribution in rat tissues: dietary phylloquinone is a source of tissue menaquinone-4. Br J Nutr. 1994;72:415-425.
12. Will BH, Usui Y, Suttie JW. Comparative metabolism and requirement of vitamin K in chicks and rats. J Nutr. 1992;122:2354-2360.
13. Ronden JE, Drittij-Reijnders MJ, Vermeer C, Thijssen HH. Intestinal flora is not an intermediate in the phylloquinonemenaquinone-4 conversion in the rat. Biochim Biophys Acta. 1998;1379:16-22.
14. Thijssen HH, Drittij-Reijnders MJ, Fischer MA. Phylloquinone and menaquinone-4 distribution in rats: synthesis rather than uptake determines menaquinone-4 organ concentrations. J Nutr. 1996;126:537-543.
15. Davidson RT, Foley AL, Engelke JA, Suttie JW. Conversion of dietary phylloquinone to tissue menaquinone-4 is not dependent on gut bacteria. J Nutr. 1998;128:220-223.
16. Thijssen HH, Drittij-Reijnders MJ. Vitamin K status in human tissues: tissue-specific accumulation of phylloquinone and menaquinone-4. Br J Nutr. 1996;75:121-127.
17. Thijssen HH, Drittij MJ, Vermeer C, Schoffelen E. Menaquinone-4 in breast milk is derived from dietary phylloquinone. Br J Nutr. 2002;87:219-226.
18. 3H in the rat. Biochemistry. 1969;8:1141-1146.
19. Dam H. The antihaemorrhagic vitamin of the chick: occurrence and chemical nature. Nature (Lond). 1935;135:652-653.
20. Morris DP, Soute BA, Vermeer C, Stafford DW. Characterization of the purified vitamin K-dependent glutamyl carboxylase. J Biol Chem. 1993;268:8735-8742.
21. 3 as cofactors for the hepatic vitamin Kdependent carboxylase. Biochim Biophys Acta. 1990;1034:170-175.
22. Groenen-van Dooren MM, Soute BA, Jie KS, Thijssen HH, Vermeer C. The relative effects of phylloquinone and menaquinone on the blood coagulation factor synthesis in vitamin Kdeficient rats. Biochem Pharmacol. 1993;46:433-437.
23. Lian JB, Friedman PA. The vitamin K-dependent synthesis of γ-carboxyglutamic acid by bone microsome. J Biol Chem. 1978;253:6623-6626.
24. 2 metabolism in human osteoblasts. Osteoporos Int. 2001;12:680-687.
25. Suhara Y, Murakami A, Nakagawa K, Mizuguchi Y, Okano T. Comparative uptake, metabolism, and utilization of menaquinone-4 and phylloquinone in human cultured cell lines. Bioorganic Med Chem. 2006;14:6601-6607.
26. Shearer MJ. Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care. 2000;3:433-438.
27. Vermeer C, Knapen MH, Schurgers LJ. Vitamin K and metabolic bone disease. J Clin Pathol. 1998;51:424-426.
28. Benzakour O, Kanthou C. The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. Blood. 2000;95:2008-2014.
29. Shanahan CM, Proudfood D, Farzaneh-Far A, Weissberg PL. The role of Gla-proteins in vascular calcification. Crit Rev Eukaryot Gene Expr. 1998;8:357-375.
30. Tsaioun KI. Vitamin K-dependent proteins in the developing and aging nervous system. Nutr Rev. 1999;57:231-240.
31. Yagami K, Suh J-Y, Enomoto-Iwamoto M, et al. Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. J Cell Biol. 1999;147:1097-1108.
32. U.S. Department of Agriculture. USDA provisional table on the vitamin K content of foods, 1994. Available at: http://www.nal.usda.gov/fnic/foodcomp/ Data/Other/pt104.pdf. Accessed October 20, 2006.
33. 1 (phylloquinone) content of foods: a provisional table. J Food Comp Anal. 1993;6:109-120.
34. McKeown NM, Rasmussen HM, Charnley JM, Wood RJ, Booth SL. Accuracy of phylloquinone (vitamin K1) data in 2 nutrient databases as determined by direct laboratory analysis of diets. J Am Diet Assoc. 2000;100:1201-1204.
35. U.S. Department of Agriculture ARS. USDA national nutrient database for standard reference, release 18, 2005. Available at: http://www.nal.usda.gov/ fnic/foodcomp. Accessed October 20, 2006.
36. Booth SL, Sadowski JA, Pennington JA. Phylloquinone (vitamin K1) content of foods in the U.S. Food and Drug Administration's Total Diet Study. J Agric Food Chem. 1995;43:1574-1579.
37. Piironen VI, Koivu TJ, Tammisalo O, Mattila PH. Determination of phylloquinone in oils, margarines and butter by high-performance liquid chromatography with electrochemical detection. Food Chem. 1997;59:473-480.
38. Koivu TJ, Piironen VI, Henttonen SK, Mattila PH. Determination of phylloquinone in vegetables, fruits, and berries by highperformance liquid chromatography with electrochemical detection. J Agric Food Chem. 1997;45:4644-4649.
39. Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J Nutr. 1996;126(4 Suppl): 1181S-1186S.
40. Dismore ML, Haytowitz DB, Gebhardt SE, Peterson JW, Booth SL. Vitamin K content of nuts and fruits in the US diet. J Am Diet Assoc. 2003;103:1650-1652.
41. Elder SJ, Haytowitz DB, Howe J, Peterson JW, Booth SL. Vitamin K contents of meat, dairy and fast food in the U.S. diet. J Agric Food Chem. 2006;54:463-467.
42. Booth SL, Pennington T, Sadowski JA. Food sources and dietary intakes of vitamin K1 (phylloquinone) in the American diet: data from the FDA Total Diet Study. J Am Diet Assoc. 1996;96:149-154.
43. Booth SL, Webb R, Peters JC. Assessment of phylloquinone and dihydrophylloquinone dietary intakes among a nationally representative sample of US consumers using 14-day food diaries. J Am Diet Assoc. 1999;99:1072-1076.
44. Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. J Nutr. 1998;128:785-788.
45. Booth SL, Tucker KL, McKeown NM, Davidson KW, Dallal GE, Sadowski JA. Relationships between dietary intakes and fasting plasma concentrations of fat-soluble vitamins in humans. J Nutr. 1997;127:587-592.
46. Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium and Zinc. Washington, DC: National Academy Press; 2001.
47. Kodaka K, Ujiie T, Ueno T, Saito M. Contents of vitamin K1 and chlorophyll in green vegetables. J Jpn Soc Nutr Food Sci. 1986;39:124-126.
48. Lichtenthaler HK. The plant prenyllipids, including carotenoids, chlorophylls and prenylquinones. In: Moore T, ed. Plant Lipids. Boca Raton, FL: CRC Press, Inc; 1993:421-464.
49. Damon M, Zhang NZ, Haytowitz DB, Booth SL. Phylloquinone (vitamin K1) content of vegetables. J Food Comp Anal. 2005;18:751-758.
50. Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Haemostasis. 2000;30:298-307.
51. Conly JM, Stein K. Quantitative and qualitative measurements of K vitamins in human intestinal contents. Am J Gastroenterol. 1992;87:311-316.
52. Shearer MJ. Vitamin K. Lancet. 1995;345:229-234.
53. Ichihashi T, Takagishi Y, Uchida K, Yamada H. Colonic absorption of menaquinone-4 and menaquinone-9 in rats. J Nutr. 1992;122:506-512.
54. Uchida K, Nomura Y, Takase H, Harauchi Y, Yoshizaki T, Nakao H. Effects of vitamin K-deficient diets and fasting on blood coagulation factors in conventional and germ-free rats. Jpn J Pharmacol. 1986;40:115-122.
55. Lipsky JJ. Nutritional sources of vitamin K. Mayo Clin Proc. 1994;69:462-466.
56. Davidson KW, Booth SL, Dolnikowski GG, Sadowski JA. The conversion of phylloquinone to 2',3'-dihydrophylloquinone during hydrogenation of vegetable oils. J Agric Food Chem. 1996;44:980-983.
57. Erkkila AT, Lichtenstein AH, Jacques PF, Hu FB, Wilson PW, Booth SL. Determinants of plasma dihydrophylloquinone in men and women. Br J Nutr. 2005;93:701-708.
58. Booth SL, Pennington JA, Sadowski JA. Dihydro-vitamin K: primary food sources and estimated intakes in the American diet. Lipids. 1996;31:715-720.
59. Booth SL, Davidson KW, Lichtenstein AH, Sadowski JA. Plasma concentrations of dihydro-vitamin K1 following dietary intake of a hydrogenated vitamin K1-rich vegetable oil. Lipids. 1996;31:709-713.
60. Booth SL, Lichtenstein AH, O'Brien-Morse M, et al. Effects of a hydrogenated form of vitamin K on bone formation and resorption. Am J Clin Nutr. 2001;74:783-790.
61. Garber AK, Binkley NC, Krueger DC, Suttie JW. Comparison of phylloquinone bioavailability from food sources or a supplement in human subjects. J Nutr. 1999;129:1201-1203.
62. Gijsbers BL, Jie K, Vermeer C. Effect of food composition on vitamin K absorption in human volunteers. Br J Nutr. 1996;76:223-229.
63. Booth SL, Lichtenstein AH, Dallal GE. Phylloquinone absorption from phylloquinone-fortified oil is greater than from a vegetable in younger and older men and women. J Nutr. 2002;132:2609-2612.
64. Booth SL, O'Brien ME, Dallal GE, Davidson KW, Gundberg CM. Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults. Am J Clin Nutr. 1999;70:368-377.
65. Erkkila AT, Lichtenstein AH, Dolnikowski GG, et al. Plasma transport of vitamin K in men using deuterium-labeled collard greens. Metabolism. 2004;53:215-221.
66. Schurgers LJ, Vermeer C. Differential lipoprotein transport pathways of K-vitamins in healthy subjects. Biochim Biophys Acta. 2002;1570:27-32.
67. McKeown NM, Jacques PF, Gundberg CM, et al. Dietary and nondietary determinants of vitamin K biochemical measures in men and women. J Nutr. 2002;132:1329-1334.
68. Sadowski JA, Hood SJ, Dallal GE, Garry PJ. Phylloquinone in plasma from elderly and young adults: factors influencing its concentration. Am J Clin Nutr. 1989;50:100-108.
69. Cham BE, Smith JL, Colquhoun DM. Interdependence of serum concentrations of vitamin K1, vitamin E, lipids, apolipoprotein A1, and apolipoprotein B: importance in assessing vitamin status. Clin Chim Acta. 1999;287:45-57.
70. Beaven SR, Prentice A, Stirling DM, et al. Ethnic differences in osteocalcin γ-carboxylation, plasma phylloquinone (vitamin K1) and apolipoprotein E genotype. Eur J Clin Nutr. 2005;59:72-81.
71. Weintraub MS, Eisenberg S, Breslow JL. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J Clin Invest. 1987;80:1571-1577.
72. Saupe J, Shearer MJ, Kohlmeier M. Phylloquinone transport and its influence on γ-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am J Clin Nutr. 1993;58:204-208.
73. Kohlmeier M, Salomon A, Saupe J, Shearer MJ. Transport of vitamin K to bone in humans. J Nutr. 1996;126(4 Suppl):1192S-1196S.
74. Newman P, Bonello F, Wierzbicki AS, Lumb P, Savidge GF, Shearer MJ. The uptake of lipoprotein-borne phylloquinone (vitamin K1) by osteoblasts and osteoblast-like cells: role of heparan sulfate proteoglycans and apolipoprotein E. J Bone Miner Res. 2002;17:426-433.
75. Shiraki M, Shiraki Y, Aoki C, et al. Association of bone mineral density with apolipoprotein E phenotype. J Bone Miner Res. 1997;12:1438-1445.
76. Kohlmeier M, Saupe J, Schaefer K, Asmus G. Bone fracture history and prospective bone fracture risk of hemodialysis patients are related to apolipoprotein E genotype. Calcif Tissue Int. 1998;62:278-281.
77. Cauley JA, Zmuda JM, Yaffe K, et al. Apolipoprotein E polymorphism: a new genetic marker of hip fracture risk: the study of osteoporotic fractures. J Bone Miner Res. 1999;14:1175-1181.
78. Booth SL, Tucker K, Chen H, et al. Dietary vitamin K intakes are associated with hip fracture but not with bone mineral density in elderly men and women. Am J Clin Nutr. 2000;71:1201-1208.
79. Wang Y, Zhang W, Zhang Y, et al. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation. 2006;113:1615-1621.
80. Adams J, Pepping J. Vitamin K in the treatment and prevention of osteoporosis and arterial calcification. Am J Health Syst Pharm. 2005;62:1574-1581.
81. Esmon CT, Sadowski JA, Suttie JW. A new carboxylation reaction: the vitamin K-dependent incorporation of H-14-CO3- into prothrombin. J Biol Chem. 1975;250:4744-4748.
82. Stenflo J, Fernlund P, Egan W, Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A. 1974;71:2730-2733.
83. Nelsestuen GL, Zytkovicz TH, Howard JB. The mode of action of vitamin K: identification of γ-carboxyglutamic acid as a component of prothrombin. J Biol Chem. 1974;249:6347-6350.
84. Magnusson S, Sottrup-Jensen L, Peterson TE, Morris HR, Dell A. Primary structure of the vitamin K-dependent part of prothrombin. FEBS Lett. 1974;44:189-193.
85. Nelsestuen GL, Suttie JW. The mode of action of vitamin K: isolation of a peptide containing the vitamin K-dependent portion of prothrombin. Proc Natl Acad Sci U S A. 1973;70:3366-3370.
86. 2+ to normal and dicoumarolinduced prothrombin. Biochem Biophys Res Commun. 1973;50:98-104.
87. 2-terminal fragment from normal and from dicoumarol-induced bovine prothrombin. J Biol Chem. 1973;248:6325-6332.
88. Hauschka PV, Lian JB, Gallop PM. Direct identification of the calcium-binding amino acid, γ-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci U S A. 1975;72:3925-3929.
89. Price PA, Poser JW, Raman N. Primary structure of the γ-carboxyglutamic acid-containing protein from bovine bone. Proc Natl Acad Sci U S A. 1976;73:3374-3375.
90. Poser JW, Esch FS, Ling NC, Price PA. Isolation and sequence of the vitamin K-dependent protein from human bone: undercarboxylation of the first glutamic acid residue. J Biol Chem. 1980;255:8685-8691.
91. 1H NMR spectroscopy. Biochemistry. 2003;42:7769-7779.
92. 3-induced mineralization in human periosteal osteoblasts. Calcif Tissue Int. 1996;59:466-473.
93. Bach AU, Anderson SA, Foley AL, Williams EC, Suttie JW. Assessment of vitamin K status in human subjects administered "minidose" warfarin. Am J Clin Nutr. 1996;64:894-902.
94. Booth SL, Martini LA, Peterson JW, Saltzman E, Dallal GE, Wood RJ. Dietary phylloquinone depletion and repletion in older women. J Nutr. 2003;133:2565-2569.
95. Price PA. Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm. 1985;42:65-108.
96. Nousiainen M, Derrick PJ, Kaartinen MT, Maenpaa PH, Rouvinen J, Vainiotalo P. A mass spectrometric study of metal binding to osteocalcin. Chem Biol. 2002;9:195-202.
97. Price PA, Williamson MK, Lothringer JW. Origin of the bone γ-carboxyglutamic acid-containing protein found in plasma and its clearance by kidney and bone. J Biol Chem. 1981;256:12760-12766.
98. Price PA, Williamson MK. Effects of warfarin on bone: studies on the vitamin K-dependent protein of rat bone. J Biol Chem. 1981;256:12754-12759.
99. Poser JW, Sunberg RT, Francis SL, Benedict JJ. The bone Gla protein as an inhibitor of seeded crystal growth [abstract]. Calcif Tissue Int. 1982;34:S26.
100. Boskey AL, Wians FH Jr, Hauschka PV. The effect of osteocalcin on in vitro lipid-induced hydroxyapatite formation and seeded hydroxyapatite growth. Calcif Tissue Int. 1985;37:57-62.
101. Hunter GK, Hauschka PV, Poole AR, Rosenberg LC, Goldberg HA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J. 1996;317:59-64.
102. Price PA, Williamson MK, Haba T. Excessive mineralization with growth plate closure in rats on chronic warfarin treatment. Proc Natl Acad Sci U S A. 1982;79:7734-7738.
103. Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature. 1996;382:448-452.
104. Boskey AL, Gadaleta S, Gundberg C, Doty SB, Ducy P, Karsenty G. Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone. 1998;23:187-196.
105. Hara K, Akiyama Y, Nakamura T, Murota S, Morita I. The inhibitory effect of vitamin K2 (menatetrenone) on bone resorption may be related to its side chain. Bone. 1995;16:179-184.
106. 2 (menatetrenone) on osteoclast-like cell formation in mouse bone marrow cultures. Eur J Pharmacol. 1994;263:181-185.
107. 2 synthesis in vitro. J Bone Miner Res. 1993;8:535-542.
108. 2 inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem Biophys Res Commun. 1996;220:515-519.
109. 2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem. 2003;278:43919-43927.
110. Sokoll LJ, Sadowski JA. Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult population. Am J Clin Nutr. 1996;63:566-573.
111. Sokoll LJ, Booth SL, O'Brien ME, Davidson KW, Tsaioun KI, Sadowski JA. Changes in serum osteocalcin, plasma phylloquinone, and urinary γ-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjects. Am J Clin Nutr. 1997;65:779-784.
112. Gundberg CM, Nieman SD, Abrams S, Rosen H. Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J Clin Endocrinol Metab. 1998;83:3258-3266.
113. Ferland G, Sadowski JA, O'Brien ME. Dietary induced subclinical vitamin K deficiency in normal human subjects. J Clin Invest. 1993;91:1761-1768.
114. Hara K, Kobayashi M, Akiyama Y. Comparison of inhibitory effects of warfarin on γ-carboxylation between bone and liver in rats. J Bone Miner Metab. 2005;23:366-372.
115. Tsugawa N, Shiraki M, Suhara Y, Kamao M, Tanaka K, Okano T. Vitamin K status of healthy Japanese women: age-related vitamin K requirement for γ-carboxylation of osteocalcin. Am J Clin Nutr. 2006;83:380-386.
116. Lukacs JL, Booth SL, Kleerekoper M, Ansbacher R, Rock CL, Reame NE. Differential associations for menopause and age in measures of vitamin K, osteocalcin, and bone density: a crosssectional exploratory study in healthy volunteers. Menopause. 2006;13:799-808.
117. Plantalech L, Guillaumont M, Vergnaud P, Leclercq M, Delmas PD. Impairment of gamma carboxylation of circulating osteocalcin (bone Gla protein) in elderly women. J Bone Miner Res. 1991;6:1211-1216.
118. Binkley NC, Krueger DC, Engelke JA, Foley AL, Suttie JW. Vitamin K supplementation reduces serum concentrations of under-γ-carboxylated osteocalcin in healthy young and elderly adults. Am J Clin Nutr. 2000;72:1523-1528.
119. Binkley NC, Krueger DC, Kawahara TN, Engelke JA, Chappell RJ, Suttie JW. A high phylloquinone intake is required to achieve maximal osteocalcin γ-carboxylation. Am J Clin Nutr. 2002;76:1055-1060.
120. Pettifor JM, Benson R. Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J Pediatr. 1975;86:459-462.
121. 1 in osteoporosis. J Clin Endocrinol Metab. 1985;60:1268-1269.
122. Hodges SJ, Pilkington MJ, Stamp TCB, et al. Depressed levels of circulating menaquinones in patients with osteoporotic fractures of the spine and femoral neck. Bone. 1991;12:387-389.
123. 2 decreased in elderly women with hip fracture. J Bone Miner Res. 1993;8:1241-1245.
124. Tamatani M, Morimoto S, Nakajima M, et al. Participation of decreased circulating levels of vitamin K in bone mineral loss of elderly men. J Bone Miner Res. 1995;10:S248.
125. Tamatani M, Morimoto S, Nakajima M, et al. Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men. Metabolism. 1998;47:195-199.
126. Kanai T, Takagi T, Masuhiro K, Nakamura M, Iwata M, Saji F. Serum vitamin K and bone mineral density in post-menopausal women. Int J Gynaecol Obstet. 1997;56:25-30.
127. Booth SL, Kerry EB, Peterson JW, et al. Associations between vitamin K biochemical measures and bone mineral density in men and women. J Clin Endocrinol Metab. 2004;89:4904-4909.
128. Kalkwarf HJ, Khoury JC, Bean J, Elliot JG. Vitamin K, bone turnover, and bone mass in girls. Am J Clin Nutr. 2004;80:1075-1080.
129. Orimo H, Hashimoto T, Sakata K, Yoshimura N, Suzuki T, Hosoi T. Trends in the incidence of hip fracture in Japan, 1987-1997: the third nationwide survey. J Bone Miner Metab. 2000;18:126-131.
130. 2: possible implications for hip-fracture risk. Nutrition. 2001;17:315-321.
131. McLean RR, Booth SL, Kiel DP, et al. Association of dietary and biochemical measures of vitamin K with quantitative ultrasound of the heel in men and women. Osteoporos Int. 2006;17:600-607.
132. Feskanich D, Weber P, Willett WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr. 1999;69:74-79.
133. Booth SL, Broe KE, Gagnon DR, et al. Vitamin K intake and bone mineral density in women and men. Am J Clin Nutr. 2003;77:512-516.
134. Rejnmark L, Vestergaard P, Charles P, et al. No effect of vitamin K1 intake on bone mineral density and fracture risk in perimenopausal women. Osteoporos Int. 2006;17:1122-1132.
135. Szulc P, Chapuy M-C, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest. 1993;91:1769-1774.
136. Szulc P, Arlot M, Chapuy M-C, Duboeuf F, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res. 1994;9:1591-1595.
137. Szulc P, Chapuy M-C, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone. 1996;18:487-488.
138. Vergnaud P, Garnero P, Meunier PJ, Breart G, Kamihagi K. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab. 1997;82:719-724.
139. Jie K-S, Bots ML, Vermeer C, Witteman JCM, Grobbee DE. Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int. 1996;59:352-356.
140. Liu G, Peacock M. Age-related changes in serum undercarboxylated osteocalcin and its relationships with bone density, bone quality, and hip fracture. Calcif Tissue Int. 1998;62:286-289.
141. Knapen MH, Nieuwenhuijzen Kruseman AC, Wouters RS, Vermeer C. Correlation of serum osteocalcin fractions with bone mineral density in women during the first 10 years after menopause. Calcif Tissue Int. 1998;63:375-379.
142. Sugiyama T, Kawai S. Carboxylation of osteocalcin may be related to bone quality: a possible mechanism of bone fracture prevention by vitamin K. J Bone Miner Metab. 2001;19:146-149.
143. Schoon EJ, Muller MCA, Vermeer C, Schurgers LJ, Brummer R-JM, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut. 2001;48:473-477.
144. Kaneki M, Mizuno Y, Husoi T, et al. Serum concentration of vitamin K in elderly women with involutional osteoporosis. Jpn J Geriatr. 1995;32:195-200.
145. Kawana K, Takahashi M, Hoshino H, Kushida K. Circulating levels of vitamin K1, menaquinone-4, and menaquinone-7 in healthy elderly Japanese women and patients with vertebral fractures and patients with hip fractures. Endocr Res. 2001;27:337-343.
146. Luukinen H, Kakonen S-M, Pettersson K, et al. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J Bone Miner Res. 2000;15:2473-2478.
147. Knapen MH, Hamulyak K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med. 1989;111:1001-1005.
148. Douglas AS, Robins SP, Hutchison JD, Porter RW, Stewart A, Reid DM. Carboxylation of osteocalcin in postmenopausal osteoporotic women following vitamin K and D supplementation. Bone. 1995;17:15-20.
149. Cracium AM, Wolf J, Knapen MH, Brouns F, Vermeer C. Improved bone metabolism in female elite athletes after vitamin K supplementation. Int J Sports Med. 1998;19:479-484.
150. Braam LA, Knapen MH, Geusens P, Brouns F, Vermeer C. Factors affecting bone loss in female endurance athletes. Am J Sports Med. 2003;31:889-895.
151. 3 and estrogenprogestin therapy. Maturitas. 1999;31:161-164.
152. 2 treatment on carboxylation of osteocalcin in early postmenopausal women. Gynecol Endocrinol. 2006;22:455-459.
153. 2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease. Bone. 2005;36:61-68.
154. 1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int. 2003;73:21-26.
155. 3 on bone mineral density and coagulofibrinolysis function in postmenopausal women. Maturitas. 2002;41:211-221.
156. 1 supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin. Eur J Clin Nutr. 2000;54:626-631.
157. 2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. J Orthop Sci. 2000;5:546-551.
158. 3 in the prevention of bone loss induced by leuprolide. J Clin Endocrinol Metab. 1999;84:2700-2704.
159. 1), vitamin D and calcium: effect on bone mineral content of older women. Ann Nutr Metab. 2001;45(Suppl 1):46.
160. 3. J Bone Miner Res. 1992;7(suppl 1):S122.
161. Matsunaga S, Ito H, Sakou T. The effect of vitamin K and D supplementation on ovariectomy-induced bone loss. Calcif Tissue Int. 1999;65:285-289.
162. 3. Proc Natl Acad Sci U S A. 1989;86:4455-4459.
163. Koshihara Y, Hoshi K. Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res. 1997;12:431-438.
164. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353-373.
165. World Health Organization Scientific Group on the Prevention and Management of Osteoporosis. Prevention and Management of Osteoporosis: Report of a WHO Scientific Group. Geneva, Switzerland: World Health Organization; 2003.
166. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
167. Andrew M, Monagle P, Brooker L. Epidemiology of venous thromboembolic events. In: Andrew M, Monagle P, Brooker L, eds. Thromboembolic Complications of Infancy and Childhood. Ontario, Canada: Decker, Hamilton; 2000:111-146.
168. Howe AM, Webster WS. The warfarin embryopathy: a rat model showing maxillonasal hypoplasia and other skeletal disturbances. Teratology. 1992;46:379-390.
169. Pastoureau P, Vergnaud P, Meunier PJ. Osteopenia and boneremodeling abnormalities in warfarin-treated lambs. J Bone Miner Res. 1993;8:1417-1426.
170. Haffa A, Krueger D, Bruner J, et al. Diet- or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J Bone Miner Res. 2000;15:872-878.
171. Obrant KL, Kakonen S-M, Astermark J, et al. The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarin-treated patients from control subjects. J Bone Miner Res. 1999;14:555-560.
172. Haarlem LJM, Knapen MJH, Hamylak K, Vermeer C. Circulating osteocalcin during anticoagulant therapy. Thromb Haemost. 1988;60:79-82.
173. Caillot-Augusseau A, Vico L, Heer M, et al. Space flight is associated with rapid decreases of undercarboxylated osteocalcin and increases of markers of bone resorption without changes in their circadian variation: observations in two cosmonauts. Clin Chem. 2000;46:1136-1143.
174. Akiba T, Kurihara S, Tachibana K, et al. Vitamin K (K) increased bone mass (BM) in hemodialysis patients (Pts) with low-turnover bone disease (LTOBD). J Am Soc Nephrol. 1991;608:42P.
175. Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a double-blind placebo-controlled study. J Bone Miner Metab. 1998;16:106-112.
176. Sato Y, Honda Y, Kuno H, Oizumi K. Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. Bone. 1998;23:291-296.
177. Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int. 2000;66:1123-1128.
178. 2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res. 2000;15:515-521.
179. Iwamoto J, Takeda T, Ichimura S. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. J Orthop Sci. 2001;6:487-492.
180. 2 for bone loss in patients with primary biliary cirrhosis. J Hepatol. 2001;35:543-545.
181. Sato Y, Honda Y, Kaji M, et al. Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency. Bone. 2002;31:114-118.
182. 2) treatment on bone loss in patients with anorexia nervosa. Psychiatry Res. 2003;48:259-269.
183. Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: the Yamaguchi Osteoporosis Prevention Study. Am J Med. 2004;117:549-555.
184. 2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG). J Bone Miner Metab. 2005;23:41-47.
185. 2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007; online ahead of print: dx.doi.org/10.1007/s00198-007-0337- 9. (Pubitemid 46889558)
186. Takahashi M, Naitou K, Ohishi T, Kushida K, Miura M. Effect of vitamin K or D on undercarboxylated and intact osteocalcin in osteoporotic patients with vertebral or hip fractures. Clin Endocrinol. 2001;54:219-224.
187. 2 (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis. J Bone Miner Metab. 2003;21:161-165.
188. Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med. 1998;128:829-832.
189. Mamdani M, Upshur RE, Anderson G, Bartle BR, Laupacis A. Warfarin therapy and risk of hip fracture among elderly patients. Pharmacotherapy. 2003;23:1-4.
190. Pilon D, Castilloux A-M, Dorais M, LeLorier J. Oral anticoagulants and the risk of osteoporotic fractures among elderly. Pharmacoepidemiol Drug Saf. 2004;13:289-294.
191. Barnes C, Newall F, Ignjatovic V, et al. Reduced bone density in children on long-term warfarin. Pediatr Res. 2005;57:578-581.
192. Caraballo PJ, Gabriel SE, Castro MR, Atkinson EJ, Melton LJ. Changes in bone density after exposure to oral anticoagulants: a meta-analysis. Osteoporos Int. 1999;9:441-448.
193. Wawrznska L, Tomkowski WZ, Przedlacki J, Hajduk B, Torbicki A. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb. 2003;33:64-67.
194. Nilas L, Christiansen C. Rates of bone loss in normal women: evidence of accelerated trabecular bone loss after the menopause. Eur J Clin Invest. 1988;18:529-534.
195. Storm T, Thamsborg G, Steinich T, Genant HK, Sorensen CH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990;322:1256-1271.
196. Gennari C, Civitelli R. Glucocorticoid induced osteoporosis. Clin Rheum Dis. 1986;12:637-654.
197. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947-2953.
198. Tucker KL, Selhub J, Wilson PW, Rosenberg IH. Dietary intake pattern relates to plasma folate and homocysteine concentrations in the Framingham Heart Study. J Nutr. 1996;126:3025-3031.
199. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fracture in patients with stroke. JAMA. 2005;293:1082-1088.
200. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-698.
201. O'Brien CL, Gage BF. Costs and effectiveness of ximelagatran for stoke prophylaxis in chronic atrial fibrillation. JAMA. 2005;293:699-706.
202. Akins PT, Feldman HA, Zoble RG, et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke. 2007;38:874-880.
203. Food and Nutrition Board of the Institute of Medicine of the National Academies. Vitamin K. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academy Press; 2000:162-196.
204. Vermeer C, Knapen MH, Jie KS, Grobbee DE. Physiological importance of extra-hepatic vitamin K-dependent carboxylation reactions. Ann N Y Acad Sci. 1992;669:21-31.
205. Rucker RB. Improved functional endpoints for use in vitamin K assessment: important implications for bone disease. Am J Clin Nutr. 1997;65:883-884.